发明申请
- 专利标题： EML4-ALK FUSION GENE
- 专利标题（中）： EML4-ALK融合基因
-
申请号： US13468730申请日： 2012-05-10
-
公开(公告)号： US20130158095A1公开(公告)日： 2013-06-20
- 发明人: Hiroyuki Mano , Sadao Kuromitsu , Nobuaki Shindo , Takatoshi Soga , Takashi Furutani
- 申请人： Hiroyuki Mano , Sadao Kuromitsu , Nobuaki Shindo , Takatoshi Soga , Takashi Furutani
- 申请人地址： JP Tokyo JP Chuo-ku
- 专利权人： CureGene K.K.,Astellas Pharma Inc.
- 当前专利权人： CureGene K.K.,Astellas Pharma Inc.
- 当前专利权人地址： JP Tokyo JP Chuo-ku
- 优先权： JP277718/2006 20061011; JP120670/2007 20070501
- 主分类号： C12N9/12
- IPC分类号： C12N9/12 ; C12N15/113 ; A61K31/506 ; C12Q1/68 ; C12Q1/48
摘要：
The present inventors found that a fusion gene present in some cancer patients is an oncogene. The present invention relates to a polypeptide as a novel fusion protein, a polynucleotide encoding the polypeptide, a vector comprising the polynucleotide, a transformed cell comprising the vector, a method for detecting the fusion protein or polynucleotide, a method for screening a therapeutic agent for cancer, and a method for treating cancer that is shown to be positive for the fusion gene. Further, the present invention relates kit, primer set, and probe useful in the detection of cancer that is shown to be positive for the fusion gene.
公开/授权文献
- US09029521B2 EML4-ALK fusion gene 公开/授权日：2015-05-12